Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Amortization of Deferred Charges: 2009-2024

Historic Amortization of Deferred Charges for Cytokinetics (CYTK) over the last 9 years, with Dec 2024 value amounting to $11.6 million.

  • Cytokinetics' Amortization of Deferred Charges rose 62.02% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 421.80%. This contributed to the annual value of $11.6 million for FY2024, which is 57.46% up from last year.
  • As of FY2024, Cytokinetics' Amortization of Deferred Charges stood at $11.6 million, which was up 57.46% from $7.3 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Amortization of Deferred Charges peaked at $11.6 million during FY2024, and registered a low of $5.7 million during FY2022.
  • In the last 3 years, Cytokinetics' Amortization of Deferred Charges had a median value of $7.3 million in 2023 and averaged $8.2 million.
  • In the last 5 years, Cytokinetics' Amortization of Deferred Charges soared by 622.52% in 2020 and then dropped by 20.04% in 2022.
  • Yearly analysis of 5 years shows Cytokinetics' Amortization of Deferred Charges stood at $6.6 million in 2020, then grew by 7.30% to $7.1 million in 2021, then dropped by 20.04% to $5.7 million in 2022, then increased by 28.86% to $7.3 million in 2023, then spiked by 57.46% to $11.6 million in 2024.